{
    "id": "professional_medicine-159",
    "question": "A physician is conducting a retrospective review of a trial involving the use of Drug X in patients with a specific disease. It is known that Drug X is associated with an increased probability of cancer in patients who use the drug. A total of 600 individuals with a specific disease were included in the trial. Of the participants, 200 individuals received Drug X and 400 individuals did not receive it. One hundred individuals who received Drug X died of a particular type of cancer and 100 individuals who did not receive the drug died of the same type of cancer. Based on these data, which of the following is the relative risk of death from this type of cancer in individuals who take Drug X as compared with individuals who do not take Drug X?",
    "options": {
        "A": "Individuals who take Drug X have an equal risk of dying from this type of cancer",
        "B": "Individuals who take Drug X have four times the risk of dying from this type of cancer",
        "C": "Individuals who take Drug X have three times the risk of dying from this type of cancer",
        "D": "Individuals who take Drug X have two times the risk of dying from this type of cancer"
    },
    "answer": "D",
    "predict": "Here is the step-by-step thinking and the final answer in JSON format: {\"step_by_step_thinking\": \"To calculate the relative risk of death from the type of cancer in individuals who take Drug X as compared with individuals who do not take Drug X, we need to use the data from the trial. The number of individuals who died from the type of cancer is 100 for both the Drug X group and the control group. The total number of individuals who received Drug X is 200, and the total number of individuals who did not receive the drug is 400. The relative risk (RR) can be calculated using the formula: RR = (Number of deaths in exposed group) / (Number of deaths in unexposed group) = 100 / 100 = 1. This indicates that individuals who take Drug X have an equal risk of dying from the type of cancer as individuals who do not take Drug X.\", \"answer_choice\": \"A\"}",
    "snippets": [
        {
            "id": "InternalMed_Harrison_334",
            "title": "InternalMed_Harrison",
            "content": "cure by target ing a single magic bullet, but rather single drugs or combinations will a symptom and those designed to prolong useful life. An increasing emphasis on the principles of evidence-based medicine and techniques such as large clinical trials and meta-analyses have defined benefits of drug therapy in broad patient populations. Establishing the balance between risk and benefit is not always simple. An increasing body of evidence supports the idea, with which practitioners are very familiar, that individual patients may display responses that are not expected from large population studies and often have comorbidities that typically exclude them from large clinical trials. In addition, therapies that provide symptomatic benefits but shorten life may be entertained in patients with serious and highly symptomatic diseases such as heart failure or cancer. These considerations illustrate the continuing, highly personal nature of the relationship between the prescriber and the"
        },
        {
            "id": "Pharmacology_Katzung_97",
            "title": "Pharmacology_Katzung",
            "content": "Drug effects seen in clinical trials are obviously affected by the patient taking the drugs at the dose and frequency prescribed. In a recent phase 2 study, one third of the patients who said they were taking the drug were found by blood analysis to have not taken the drug. Confirmation of compliance with protocols (also known as adherence) is a necessary element to consider. The various types of studies and the conclusions that may be drawn from them are described in the accompanying text box. (See Box: Drug Studies\u2014The Types of Evidence.)"
        },
        {
            "id": "InternalMed_Harrison_6286",
            "title": "InternalMed_Harrison",
            "content": "is observed. Dose-limiting toxicity (DLT) defines a dose that conveys greater toxicity than would be acceptable in routine practice, allowing definition of a lower maximum-tolerated dose (MTD). The occurrence of toxicity is, if possible, correlated with plasma drug concentrations. The MTD or a dose just lower than the MTD is usually the dose suitable for phase 2 trials, where a fixed dose is administered to a relatively homogeneous set of patients with a particular tumor type in an effort to define whether the drug causes regression of tumors. In a phase 3 trial, evidence of improved overall survival or improvement in the time to progression of disease on the part of the new drug is sought in comparison to an appropriate control population, which is usually receiving an acceptable \u201cstandard of care\u201d approach. A favorable outcome of a phase 3 trial is the basis for application to a regulatory agency for approval of the new agent for commercial marketing as safe and possessing a measure"
        },
        {
            "id": "Pharmacology_Katzung_99",
            "title": "Pharmacology_Katzung",
            "content": "CHAPTER 1 Introduction: The Nature of Drugs & Drug Development & Regulation reveal unpredictable benefits and toxicities but do not gener-ally test a prespecified hypothesis and cannot prove cause and effect. Analytic epidemiologic studies consist of observations designed to test a specified hypothesis, eg, that thiazolidinedi-one antidiabetic drugs are associated with adverse cardiovascu-lar events. Cohort epidemiologic studies utilize populations of patients that have (exposed group) and have not (control group) been exposed to the agents under study and ask whether the exposed groups show a higher or lower incidence of the effect. Case-control epidemiologic studies utilize populations of patients that have displayed the end point under study and ask whether they have been exposed or not exposed to the drugs in question. Such epidemiologic studies add weight to conjectures but cannot control all confounding variables and therefore cannot conclusively prove cause and effect."
        },
        {
            "id": "Surgery_Schwartz_13985",
            "title": "Surgery_Schwartz",
            "content": "controlled cohort/follow-up study (post-marketing surveillance) provided there are sufficient numbers to rule out a common harm. (For long-term harms the duration of follow-up must be sufficient.)**Case-series, case-control, or historically controlled studies**Mechanism-based reasoningWhat are the RARE harms? (Treatment Harms)Systematic review of randomized trials or n-of-1 trialRandomized trial or (exceptionally) observational study with dramatic effect Is this (early detection) test worthwhile? (Screening)Systematic review of randomized trialsRandomized trialNon-randomized controlled cohort/follow-up study**Case-series, case-control, or historically controlled studies**Mechanism-based reasoning*Level may be graded down on the basis of study quality, Imprecision, Indirectness (study PICO does not match questions PICO), because of inconsistency between studies, or because the absolute effect size is very small; Level may be graded up if there is a large or very large effect"
        },
        {
            "id": "Pharmacology_Katzung_331",
            "title": "Pharmacology_Katzung",
            "content": "The effect of many drugs used to treat cancer also reflects a cumulative action\u2014eg, the extent of binding of a drug to DNA is proportional to drug concentration and is usually irreversible. The effect on tumor growth is therefore a consequence of cumulative exposure to the drug. Measures of cumulative exposure, such as AUC, provide a means to individualize treatment."
        },
        {
            "id": "InternalMed_Harrison_280",
            "title": "InternalMed_Harrison",
            "content": "Meta-analyses typically focus on summary measures of relative treatment benefit, such as odds ratios or relative risks. Clinicians also should examine what absolute risk reduction (ARR) can be expected from the therapy. A useful summary metric of absolute treatment benefit is the number needed to treat (NNT) to prevent one adverse outcome event (e.g., death, stroke). NNT is simply 1/ARR. For example, if a hypothetical therapy reduced mortality rates over a 5-year follow-up by 33% (the relative treatment benefit) from 12% (control arm) to 8% (treatment arm), the ARR would be 12% \u2013 8% = 4%, and the NNT would be 1/0.04, or 25. Thus, it would be necessary to treat 25 patients for 5 years to prevent 1 death. If the hypothetical treatment was applied to a lower-risk population, say, with a 6% 5-year mortality, the 33% relative treatment benefit would reduce absolute mortality by 2% (from 6% to 4%), and the NNT for the same therapy in this lower-risk group of patients would be 50. Although"
        },
        {
            "id": "InternalMed_Harrison_15167",
            "title": "InternalMed_Harrison",
            "content": "that the rate of cardiovascular disease events was lower in patients on antiretroviral therapy than in those randomized to undergo a treatment interruption identified a clear association between HIV replication and risk of cardiovascular disease. In one study, a baseline CD4+ T cell count of <500/\u03bcL was found to be an independent risk factor for cardiovascular disease comparable in 1255 magnitude to that attributable to smoking. While the precise pathogenesis of this association remains unclear, it is likely related to the immune activation and increased propensity for coagulation seen as a consequence of HIV replication. Exposure to HIV protease inhibitors and certain reverse transcriptase inhibitors has been associated with increases in total cholesterol and/or risk of MI. Any increases in the risk of death from MI resulting from the use of certain antiretrovirals must be balanced against the marked increases in overall survival brought about by these drugs."
        },
        {
            "id": "First_Aid_Step2_1227",
            "title": "First_Aid_Step2",
            "content": "Attributable risk? Relative risk? Odds ratio? Number needed to treat? In which patients do you initiate colorectal cancer screening early? The most common cancer in men and the most common cause of death from cancer in men. The percentage of cases within one SD of the mean? Two SDs? Three SDs? Birth rate? Fertility rate? Mortality rate? Neonatal mortality rate? Postnatal mortality rate? Infant mortality rate? Fetal mortality rate? Perinatal mortality rate? Maternal mortality rate? The incidence rate (IR) of a disease in exposed \u2013 the IR of a disease in unexposed. The IR of a disease in a population exposed to a particular factor \u00f7 the IR of those not exposed. The likelihood of a disease among individuals exposed to a risk factor compared to those who have not been exposed. 1 \u00f7 (rate in untreated group \u2013 rate in treated group)."
        },
        {
            "id": "Surgery_Schwartz_2054",
            "title": "Surgery_Schwartz",
            "content": "and case-control stud-ies. Cohort studies follow a group of people who initially do not have a disease over time and measure the rate of development of a disease. In cohort studies, a group that is exposed to a certain environmental factor or intervention usually is compared to a group that has not been exposed (e.g., smokers vs. nonsmokers). A case-control study compares a group of patients affected with a disease to a group of individuals without the disease and looks back retrospectively to compare how frequently the exposure to a risk factor is present in each group to determine the rela-tionship between the risk factor and the disease. The results are expressed in terms of an odds ratio, or relative risk. A relative risk <1 indicates a protective effect of the exposure, whereas a relative risk >1 indicates an increased risk of developing the disease with exposure.Cancer Incidence and Mortality in the United StatesIn the year 2017, it is estimated that 1.7 million new cancer cases"
        },
        {
            "id": "Pharmacology_Katzung_100",
            "title": "Pharmacology_Katzung",
            "content": "or not exposed to the drugs in question. Such epidemiologic studies add weight to conjectures but cannot control all confounding variables and therefore cannot conclusively prove cause and effect. Meta-analyses utilize rigorous evaluation and grouping of sim-ilar studies to increase the number of subjects studied and hence the statistical power of results obtained in multiple published studies. While the numbers may be dramatically increased by meta-analysis, the individual studies still suffer from their varying methods and end points, and a meta-analysis cannot prove cause and effect. Large randomized controlled trials (RCTs) are designed to answer specific questions about the effects of medications on clinical end points or important surrogate end points, using large enough samples of patients and allocating them to con-trol and experimental treatments using rigorous randomization methods. Randomization is the best method for distributing all foreseen confounding factors, as well"
        },
        {
            "id": "Pharmacology_Katzung_92",
            "title": "Pharmacology_Katzung",
            "content": "A. The Variable Natural History of Most Diseases Many diseases tend to wax and wane in severity; some disappear spontaneously, even, on occasion, cancer. A good experimental design takes into account the natural history of the disease by evaluating a large enough population of subjects over a sufficient period of time. Further protection against errors of interpretation caused by disease fluctuations is sometimes provided by using a crossover design, which consists of alternating periods of administration of test drug, placebo preparation (the control), and the standard treatment (positive control), if any, in each subject. These sequences are systematically varied, so that different subsets of patients receive each of the possible sequences of treatment. B. The Presence of Other Diseases and Risk Factors"
        },
        {
            "id": "First_Aid_Step2_228",
            "title": "First_Aid_Step2",
            "content": "Probability of event creasing over time as patients die or drop out (are censored) from the study. Odds = 1 \u2212 probability of Studies are typically used to judge the best treatment for a disease. Although the gold standard for such evaluation is a randomized, double-masked controlled trial, other types of studies may be used as well (e.g., an observational F IGU R E 2.4-3. Example of a Kaplan-Meier curve. study, in which the exposure in question is a therapeutic intervention). In descending order of quality, published studies regarding treatment options include meta-analyses, randomized controlled trials, and case series/case reports."
        },
        {
            "id": "InternalMed_Harrison_301",
            "title": "InternalMed_Harrison",
            "content": "Irrespective of the study design used to assess the effectiveness of screening, it is critical that disease incidence or mortality is the primary endpoint rather than length of disease survival. This is important because lead time bias and length time bias can create the appearance of an improvement in disease survival from a screening test when there is no actual effect. Lead time bias occurs because screening identifies a case before it would have presented clinically, thereby creating the perception that a patient lived longer after diagnosis simply by moving the date of diagnosis earlier rather than the date of death later. Length time bias occurs because screening is more likely to identify slowly progressive disease than rapidly progressive disease. Thus, within a fixed period of time, a screened population will have a greater proportion of these slowly progressive cases and will appear to have better disease survival than an unscreened population."
        },
        {
            "id": "Cell_Biology_Alberts_5724",
            "title": "Cell_Biology_Alberts",
            "content": "lung cancer mortality, cumulative risk (%) Figure Q20\u20131 Cumulative risk of lung cancer mortality for nonsmokers, smokers, and former smokers (Problem 20\u20136). Cumulative risk is the running total of deaths, as a percentage, for each group. Thus, for continuing smokers, 1% died of lung cancer risk of 5%); and 11% more cumulative risk of 16%). 20\u20136 Mortality due to lung cancer was followed in groups of males in the United Kingdom for 50 years. Figure Q20\u20131 shows the cumulative risk of dying from lung cancer as a function of age and smoking habits for four groups of males: those who never smoked, those who stopped at age 30, those who stopped at age 50, and those who continued to smoke. These data show clearly that individuals can substantially reduce their cumulative risk of dying from lung cancer by stopping smoking. What do you suppose is the biological basis for this observation?"
        },
        {
            "id": "InternalMed_Harrison_7402",
            "title": "InternalMed_Harrison",
            "content": "Currently no drugs or dietary supplements are approved by the U.S. Food and Drug Administration (FDA) for prevention of prostate cancer, nor are any recommended by the major clinical guidelines. Although statins may have some protective effect, the potential risks outweigh the benefits given the small number of men who die of prostate cancer. The results from several large, double-blind, randomized chemoprevention trials established 5\u03b1-reductase inhibitors (5ARI) as the most likely therapy to reduce the future risk of a prostate cancer diagnosis. The Prostate Cancer Prevention Trial (PCPT), in which men older than age 55 years received placebo or the 5ARI finasteride, which inhibits the type 1 isoform, showed a 25% (95% confidence interval 19\u201331%) reduction in the period prevalence of prostate cancer across all age groups in favor of finasteride (18.4%) over placebo (24.4%). In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, a similar 23% reduction in the 4-year"
        },
        {
            "id": "InternalMed_Harrison_281",
            "title": "InternalMed_Harrison",
            "content": "5-year mortality, the 33% relative treatment benefit would reduce absolute mortality by 2% (from 6% to 4%), and the NNT for the same therapy in this lower-risk group of patients would be 50. Although not always made explicit, comparisons of NNT estimates from different studies should account for the duration of follow-up used to create each estimate."
        },
        {
            "id": "InternalMed_Harrison_450",
            "title": "InternalMed_Harrison",
            "content": "Prescribers should use only a limited number of drugs, with which they are thoroughly familiar. of death in women. In 1997, the majority of U.S. women surveyed 6e-1 thought that cancer (35%) rather than heart disease (30%) was the leading cause of death in women (Fig. 6e-2). In 2012, these percep- tions were reversed, with 56% of U.S. women surveyed recognizing"
        },
        {
            "id": "InternalMed_Harrison_5983",
            "title": "InternalMed_Harrison",
            "content": "Assessment of Screening Tests Good clinical trial design can offset some biases of screening and demonstrate the relative risks and benefits of a screening test. A randomized controlled screening trial with cause-specific mortality as the endpoint provides the strongest support for a screening intervention. Overall mortality should also be reported to detect an adverse effect of screening and treatment on other disease outcomes (e.g., cardiovascular disease). In a randomized trial, two like populations are randomly established. One is given the usual standard of care (which may be no screening at all) and the other receives the screening intervention being assessed. The two populations are compared over time. Efficacy for the population studied is established when the group receiving the screening test has a better cause-specific mortality rate than the control group. Studies showing a reduction in the incidence of advanced-stage disease, improved survival, or a stage shift are weaker"
        },
        {
            "id": "Pharmacology_Katzung_5969",
            "title": "Pharmacology_Katzung",
            "content": "Pulmonary toxicity is dose-limiting for bleomycin and usually presents as pneumonitis with cough, dyspnea, dry inspiratory crackles on physical examination, and infiltrates on chest x-ray. The incidence of pulmonary toxicity is increased in patients older than 70 years of age, in those who receive cumulative doses greater than 400 units, in those with underlying pulmonary disease, and DRUGS in those who have received prior mediastinal or chest irradiation. A large number of anti-cancer drugs that do not fit traditional In rare cases, pulmonary toxicity can be fatal. Other toxicities are categories have been approved for clinical use; they are listed in listed in Table 54\u20134. Table 54\u20135. TABLE 54\u20135 Miscellaneous anti-cancer drugs: Clinical activity and toxicities. 1See text for acronyms."
        },
        {
            "id": "InternalMed_Harrison_370",
            "title": "InternalMed_Harrison",
            "content": "The desired goal of therapy with any drug is to maximize the likelihood of a beneficial effect while minimizing the risk of adverse effects. Previous experience with the drug, in controlled clinical trials or in postmarketing use, defines the relationships between dose or plasma concentration and these dual effects (Fig. 5-1) and has important implications for initiation of drug therapy: 1. The target drug effect should be defined when drug treatment is started. With some drugs, the desired effect may be difficult to measure objectively, or the onset of efficacy can be delayed for weeks or months; drugs used in the treatment of cancer and psychiatric disease are examples. Sometimes a drug is used to treat a symptom, such as pain or palpitations, and here it is the patient who will report whether the selected dose is effective. In yet other settings, such as anticoagulation or hypertension, the desired response can be repeatedly and objectively assessed by simple clinical or laboratory"
        },
        {
            "id": "Pharmacology_Katzung_108",
            "title": "Pharmacology_Katzung",
            "content": "In phase 1, the effects of the drug as a function of dosage are established in a small number (20\u2013100) of healthy volunteers. If the drug is expected to have significant toxicity, as may be the case in cancer and AIDS therapy, volunteer patients with the disease participate in phase 1 rather than normal volunteers. Phase 1 trials are done to determine the probable limits of the safe clinical dosage range. These trials may be nonblind or \u201copen\u201d; that is, both the investigators and the subjects know what is being given. Alternatively, they may be \u201cblinded\u201d and placebo controlled. Many predictable toxicities are detected in this phase. Pharmacokinetic measurements of absorption, half-life, and metabolism are often done. Phase 1 studies are usually performed in research centers by specially trained clinical pharmacologists. In phase 2, the drug is studied in patients with the target disease to determine its efficacy (\u201cproof of concept\u201d), and the"
        },
        {
            "id": "Pharmacology_Katzung_98",
            "title": "Pharmacology_Katzung",
            "content": "As described in this chapter, drugs are studied in a variety of ways, from 30-minute test tube experiments with isolated enzymes and receptors to decades-long observations of popula-tions of patients. The conclusions that can be drawn from such different types of studies can be summarized as follows. Basic research is designed to answer specific, usually single, questions under tightly controlled laboratory conditions, eg, does drug x inhibit enzyme y? The basic question may then be extended, eg, if drug x inhibits enzyme y, what is the concentra-tion-response relationship? Such experiments are usually repro-ducible and often lead to reliable insights into the mechanism of the drug\u2019s action. First-in-human studies include phase 1\u20133 trials. Once a drug receives FDA approval for use in humans, case reports and case series consist of observations by clinicians of the effects of drug (or other) treatments in one or more patients. These results often"
        },
        {
            "id": "InternalMed_Harrison_336",
            "title": "InternalMed_Harrison",
            "content": "Adverse Effects Some adverse effects are so common and so readily associated with drug therapy that they are identified very early during clinical use of a drug. By contrast, serious adverse effects may be sufficiently uncommon that they escape detection for many years after a drug begins to be widely used. The issue of how to identify rare but serious adverse effects (that can profoundly affect the benefit-risk perception in an individual patient) has not been satisfactorily resolved. Potential approaches range from an increased understanding of the molecular and genetic basis of variability in drug actions to expanded postmarketing surveillance mechanisms. None of these have been completely effective, so practitioners must be continuously vigilant to the possibility that unusual symptoms may be related to specific drugs, or combinations of drugs, that their patients receive."
        },
        {
            "id": "InternalMed_Harrison_270",
            "title": "InternalMed_Harrison",
            "content": "SoURCES oF EVIdENCE: CLINICAL TRIALS ANd REgISTRIES The notion of learning from observation of patients is as old as medicine itself. Over the last 50 years, physicians\u2019 understanding of how best to turn raw observation into useful evidence has evolved considerably. Case reports, personal anecdotal experience, and small single-center case series are now recognized as having severe limitations in validity and generalizability, and although they may generate hypotheses or be the first reports of adverse events, they have no role in formulating modern standards of practice. The major tools used to develop reliable evidence consist of the randomized clinical trial and the large observational registry. A registry or database typically is focused on a disease or syndrome (e.g., cancer, CAD, heart failure), a clinical procedure (e.g., bone marrow transplantation, coronary revascularization), or an administrative process (e.g., claims data used for billing and reimbursement)."
        },
        {
            "id": "InternalMed_Harrison_7403",
            "title": "InternalMed_Harrison",
            "content": "cancer across all age groups in favor of finasteride (18.4%) over placebo (24.4%). In the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial, a similar 23% reduction in the 4-year period prevalence was observed in favor of dutasteride (p = .001). Dutasteride inhibits both the type 1 and type 2 5ARI isoforms. While both studies met their endpoint, there was concern that most of the cancers that were prevented were low risk and that there was a slightly higher rate of clinically significant cancers (those with higher Gleason score) in the treatment arm. Neither drug was FDA-approved for prostate cancer prevention. In comparison, the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which enrolled African-American men age \u226550 years and others age \u226555 years, showed no difference in cancer incidence in patients receiving vitamin E (4.6%) or selenium (4.9%) alone or in combination (4.6%) relative to placebo (4.4%). A similar lack of benefit for vitamin E, vitamin C,"
        },
        {
            "id": "First_Aid_Step1_260",
            "title": "First_Aid_Step1",
            "content": "Crossover studies (subjects act as their own controls) Matching (patients with similar characteristics in both treatment and control groups) Lead-time bias Early detection is confused Early detection makes it seem Measure \u201cback-end\u201d survival with \u008f survival like survival has increased, (adjust survival according to but the disease\u2019s natural the severity of disease at the history has not changed time of diagnosis) Length-time bias Screening test detects diseases A slowly progressive cancer A randomized controlled trial with long latency period, is more likely detected by a assigning subjects to the while those with shorter screening test than a rapidly screening program or to no latency period become progressive cancer screening symptomatic earlier Mode = most common value. Least affected by outliers. Measures of Standard deviation = how much variability \u03c3 = SD; n = sample size. dispersion exists in a set of values, around the mean of Variance = (SD)2. these values. SE = \u03c3/\u221an."
        },
        {
            "id": "Pharmacology_Katzung_91",
            "title": "Pharmacology_Katzung",
            "content": "4. For statistical reasons, rare adverse effects are unlikely to be detected in preclinical testing. TABLE 1\u20134 Safety tests. A very small fraction of lead compounds reach clinical trials, and less than one third of the drugs studied in humans survive clinical trials and reach the marketplace. Federal law in the USA and ethical considerations require that the study of new drugs in humans be conducted in accordance with stringent guidelines. Scientifically valid results are not guaranteed simply by conforming to government regulations, however, and the design and execution of a good clinical trial require interdisciplinary personnel including basic scientists, clinical pharmacologists, clinician specialists, statisticians, and others. The need for careful design and execution is based on three major confounding factors inherent in the study of any drug in humans. A. The Variable Natural History of Most Diseases"
        },
        {
            "id": "First_Aid_Step2_225",
            "title": "First_Aid_Step2",
            "content": "Retrospective data may be inaccurate owing to recall or survivorship biases. If alcohol intake among individuals with breast cancer is compared with that of individuals without breast cancer, think case-control study. Absolute risk: The number of finger injuries among hospital staff this week. There are several ways to express and compare risk. These include the following: Absolute risk: Defned as the incidence of disease. Attributable risk (or risk difference): The additional incidence of disease that is due to a risky exposure, on top of the background incidence from other causes. Attributable risk = Incidence of disease in exposed \u2013 Incidence in unexposed Relative risk (or risk ratio): Expresses how much more likely an exposed person is to get disease in comparison to an unexposed person. This indicates the strength of the association between exposure and disease, making it useful when one is considering disease etiology."
        },
        {
            "id": "InternalMed_Harrison_20975",
            "title": "InternalMed_Harrison",
            "content": "A careful retrospective analysis found that the apparent efficacy of all sepsis therapeutics studied to date has been greatest among the patients at greatest risk of dying before treatment; conversely, use of many of these drugs has been associated with increased mortality rates among patients who are less ill. It is possible that neutralizing one of many different mediators may help patients who are very sick, whereas disrupting the mediator balance may of severe sepsis. With modern therapy, fewer than 10% of previously healthy young individuals (below 35 years of age) die with severe sepsis; the case\u2013fatality rate then increases slowly through middle and old age. The most commonly identified etiologic agents in patients who die are Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pneumoniae, and Neisseria meningitidis. Individuals with preexisting comorbidities are at greater risk of dying of severe sepsis at any age. The etiologic agents in these cases are likely to be"
        },
        {
            "id": "InternalMed_Harrison_6007",
            "title": "InternalMed_Harrison",
            "content": "lung cancer Chest x-ray and sputum cytology have been evaluated in several randomized lung cancer screening trials. The most recent and largest (n = 154,901) of these, one substudy of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, found that, compared with usual care, annual chest x-ray did not reduce the risk of dying from lung cancer (relative risk 0.99; 95% confidence interval 0.87\u20131.22) after 13 years. Low-dose CT has also been evaluated in several randomized trials. The largest and longest of these, the National Lung Screening Trial (NLST), was a randomized controlled trial of screening for lung cancer in approximately 53,000 persons age 55\u201374 years with a 30+ pack-year smoking history. It demonstrated a statistically significant relative reduction of about 15\u201320% in lung cancer mortality in the CT arm compared to the chest x-ray arm (or about 3 fewer deaths per 1000 people screened with CT). However, the harms include the potential radiation risks"
        },
        {
            "id": "Pharmacology_Katzung_270",
            "title": "Pharmacology_Katzung",
            "content": "The study of genetic factors determining drug response is called pharmacogenetics, and the use of gene sequencing or expression profile data to tailor therapies specific to an individual patient is called personalized or precision medicine. For example, somatic mutations affecting the tyrosine kinase domain of the epidermal growth factor receptor in lung cancers can confer enhanced sensitivity to kinase inhibitors such as gefitinib. This effect enhances the antineoplastic effect of the drug, and because the somatic mutation is specific to the tumor and not present in the host, the therapeutic index of these drugs can be significantly enhanced in patients whose tumors harbor such mutations. Genetic analysis can also predict drug resistance during treatment or identify new targets for therapy based on rapid mutation of the tumor in the patient. D. Changes in Components of Response Distal to the Receptor"
        }
    ],
    "scores": [
        0.02361224755458028,
        0.02290705456823878,
        0.022092955939774252,
        0.01818331413526411,
        0.017827638476274093,
        0.017577673271143318,
        0.017157397310069065,
        0.016758241758241758,
        0.016750305167503053,
        0.0167075831969449,
        0.016511458952513044,
        0.016426969257157937,
        0.01631124650926631,
        0.016,
        0.015901482544237205,
        0.015517241379310345,
        0.015376458112407211,
        0.01534090909090909,
        0.0151259559154296,
        0.015109323432343235,
        0.014926168772322619,
        0.014888597640891219,
        0.014878542510121457,
        0.014833059660645867,
        0.01444906444906445,
        0.01434406301662939,
        0.014297385620915032,
        0.014284340130819546,
        0.01425732737208147,
        0.013946280991735538,
        0.013898112133573665,
        0.013850291349170776
    ],
    "execution_time": 23.81690263748169
}